| Market Capitalization (Millions $) |
8,485 |
| Shares
Outstanding (Millions) |
1,050 |
| Employees |
691 |
| Revenues (TTM) (Millions $) |
166 |
| Net Income (TTM) (Millions $) |
-992 |
| Cash Flow (TTM) (Millions $) |
68 |
| Capital Exp. (TTM) (Millions $) |
7 |
Business Description
Immunitybio Inc. is a biotechnology company that specializes in developing and commercializing immunotherapies for the treatment of various diseases, including cancer and infectious diseases. The company aims to harness the power of the immune system to target and eliminate diseased cells.
Immunitybio's primary focus is on developing novel immunotherapies, such as cancer vaccines and cell therapies, that can activate and enhance the immune response against cancer cells. The company's approach involves utilizing a combination of genetically engineered molecules, peptides, and viral vectors to stimulate the immune system's ability to identify and destroy cancer cells.
In addition to its cancer programs, Immunitybio is also working on developing immunotherapies for infectious diseases, such as HIV/AIDS and the novel coronaviruses. The company's goal is to leverage its expertise in immunology to create innovative treatments that can effectively combat these diseases.
Overall, Immunitybio Inc. aims to revolutionize the field of immunotherapy through its advanced scientific research, strategic collaborations, and commitment to improving patient outcomes.
Company Address: 3530 John Hopkins Court San Diego 92121 CA
Company Phone Number: 696-5235 Stock Exchange / Ticker: NASDAQ IBRX
|
8.75% 
185.09 %